7月9日，Celcuity盘中下跌5.37%，报110.27美元/股，成交额5625.14万美元。该股前一交易日曾上涨5.02%。消息面上，公司核心候选药物gedatolisib的FDA处方药用户付费法案目标审评日期定于7月17日，距今不足10天。该药物已获FDA新药申请优先审评资格，用于HR+/HER2-/PIK3CA突变晚期乳腺癌治疗，III期Viktoria-1试验数据显示三联疗法将疾病进展或死亡风险降低50%，中位无进展生存期达11.1个月。临近重大二元催化事件，市场多空博弈加剧，股价出现回调。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.